Literature DB >> 22492103

Clinical guidelines for late-onset Pompe disease.

M A Barba-Romero1, E Barrot, J Bautista-Lorite, E Gutierrez-Rivas, I Illa, L M Jimenez, M Ley-Martos, A Lopez de Munain, J Pardo, S I Pascual-Pascual, J Perez-Lopez, J Solera, J J Vilchez-Padilla.   

Abstract

Before 2006, Pompe disease or glycogenosis storage disease type II was an incurable disease whose treatment was merely palliative. The development of a recombinant human alpha-glucosidase enzymatic replacement therapy has become the first specific treatment for this illness. The aim of this guide is to serve as reference for the management of the late-onset Pompe disease, the type of Pompe disease that develops after one year of age. In the guide a group of Spanish experts make specific recommendations about diagnosis, follow-up and treatment of this illness. With regard to diagnosis, the dried blood spots method is essential as the first step for the diagnosis of Pompe disease. The confirmation of the diagnosis of Pompe disease must be made by means of an study of enzymatic activity in isolated lymphocytes or a mutation analysis of the alpha-glucosidase gene. With regard to treatment with enzymatic replacement therapy, the experts say that is effective improving or stabilizating the motor function and the respiratory function and it must be introduced when the first symptoms attributable to Pompe disease appear.

Entities:  

Mesh:

Year:  2012        PMID: 22492103

Source DB:  PubMed          Journal:  Rev Neurol        ISSN: 0210-0010            Impact factor:   0.870


  7 in total

Review 1.  [Diagnosis and therapy of late onset Pompe disease].

Authors:  A Schüller; C Kornblum; M Deschauer; M Vorgerd; B Schrank; E Mengel; Z Lukacs; D Gläser; P Young; U Plöckinger; B Schoser
Journal:  Nervenarzt       Date:  2013-12       Impact factor: 1.214

2.  Early is better? A new algorithm for early diagnosis in late onset Pompe disease (LOPD).

Authors:  Antonio Toscano; Federica Montagnese; Olimpia Musumeci
Journal:  Acta Myol       Date:  2013-10

Review 3.  Review and evaluation of the methodological quality of the existing guidelines and recommendations for inherited neurometabolic disorders.

Authors:  Linda Cassis; Elisenda Cortès-Saladelafont; Marta Molero-Luis; Delia Yubero; Maria Julieta González; Aida Ormazábal; Carme Fons; Cristina Jou; Cristina Sierra; Esperanza Castejon Ponce; Federico Ramos; Judith Armstrong; M Mar O'Callaghan; Mercedes Casado; Raquel Montero; Silvia Meavilla-Olivas; Rafael Artuch; Ivo Barić; Franco Bartoloni; Cinzia Maria Bellettato; Fedele Bonifazi; Adriana Ceci; Ljerka Cvitanović-Šojat; Christine I Dali; Francesca D'Avanzo; Ksenija Fumic; Viviana Giannuzzi; Christina Lampe; Maurizio Scarpa; Ángels Garcia-Cazorla
Journal:  Orphanet J Rare Dis       Date:  2015-12-30       Impact factor: 4.123

4.  Muscle MRI Findings in Childhood/Adult Onset Pompe Disease Correlate with Muscle Function.

Authors:  Sebastián Figueroa-Bonaparte; Sonia Segovia; Jaume Llauger; Izaskun Belmonte; Irene Pedrosa; Aída Alejaldre; Mercè Mayos; Guillermo Suárez-Cuartín; Eduard Gallardo; Isabel Illa; Jordi Díaz-Manera
Journal:  PLoS One       Date:  2016-10-06       Impact factor: 3.240

Review 5.  Practical Recommendations for Diagnosis and Management of Respiratory Muscle Weakness in Late-Onset Pompe Disease.

Authors:  Matthias Boentert; Hélène Prigent; Katalin Várdi; Harrison N Jones; Uwe Mellies; Anita K Simonds; Stephan Wenninger; Emilia Barrot Cortés; Marco Confalonieri
Journal:  Int J Mol Sci       Date:  2016-10-17       Impact factor: 5.923

6.  Characteristics of Pompe disease in China: a report from the Pompe registry.

Authors:  Yuying Zhao; Zhaoxia Wang; Jiahong Lu; Xuefan Gu; Yonglan Huang; Zhengqing Qiu; Yanping Wei; Chuanzhu Yan
Journal:  Orphanet J Rare Dis       Date:  2019-04-03       Impact factor: 4.123

7.  Understanding the ecosystem of patients with lysosomal storage diseases in Spain: a qualitative research with patients and health care professionals.

Authors:  Juan de Dios García-Díaz; Mónica López-Rodríguez; Montserrat Morales-Conejo; Antoni Riera-Mestre
Journal:  Orphanet J Rare Dis       Date:  2022-01-14       Impact factor: 4.123

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.